Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation

Web Exclusives - FDA Updates, In the News
Yvette Florio Lane

On May 2, 2019, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo; Agios Pharmaceuticals, Inc) for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved companion diagnostic test, in patients who are aged ≥75 years or who have comorbidities that preclude the use of intensive induction chemotherapy.

This is the second FDA approval for ivosidenib, which was previously approved on July 20, 2018, for the treatment of patients with relapsed or refractory AML with a susceptible IDH1 mutation.

The most recent approval of this agent was based on results from the open-label, single-arm, multicenter, clinical trial that included 28 patients with newly diagnosed AML with an IDH1 mutation.

Patients were treated with ivosidenib, which was administered orally at a dose of 500 mg daily until disease progression, development of unacceptable toxicity, or stem-cell transplantation. The primary end point of the trial was the combined complete remission (CR) and complete remission with partial hematologic improvement (CRh) rate.

Twelve (42.9%) of the 28 patients achieved CR+CRh, and 7 (41.2%) of the 17 transfusion-dependent patients achieved transfusion independence lasting ≥8 weeks. Two of the 28 patients underwent stem-cell transplantation following ivosidenib treatment.

Adverse reactions occurring in ≥25% of patients included diarrhea, fatigue, edema, decreased appetite, leukocytosis, nausea, arthralgia, abdominal pain, dyspnea, differentiation syndrome, and myalgia.

The prescribing information for ivosidenib includes a boxed warning that differentiation syndrome may occur and can be fatal if not treated.

Related Items
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Web Exclusives published on December 3, 2019 in Bladder Cancer, FDA Updates, Immunotherapy
Inrebic Receives FDA Approval for Adults with Myelofibrosis
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer
Web Exclusives published on December 2, 2019 in FDA Updates
Keytruda plus Lenvima Combo FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
November 18, 2019 — Oncology News & Updates
Web Exclusives published on November 18, 2019 in Drug Updates, FDA Updates, Hepatocellular Carcinoma, In the News, Lymphoma
November 11, 2019 — Oncology News & Updates
Web Exclusives published on November 11, 2019 in FDA Updates, In the News
FDA News
TOP - November 2019, Vol 12, No 4 published on November 7, 2019 in FDA Updates
November 4, 2019 — Oncology News & Updates
Web Exclusives published on November 5, 2019 in Financial Toxicity, Head and Neck Cancer, Hematologic Cancers, In the News, Leukemia
Last modified: June 4, 2019